What is ArteraAI Prostate Test?
ArteraAI is a precision medicine company specializing in AI-driven tests to personalize cancer therapy. Their flagship product, the ArteraAI Prostate Test, is designed for patients with localized prostate cancer.
This test leverages multimodal artificial intelligence (MMAI) to analyze digital pathology images and clinical data. It predicts a patient's response to specific treatments and offers prognostic insights into long-term outcomes. The ArteraAI Prostate Test provides individualized results, empowering clinicians to make informed, personalized treatment decisions in collaboration with their patients. The test does not consume tissue, and results are typically available within 2-3 days.
Features
- Predictive Performance: Predicts a patient's response to specific prostate cancer treatments.
- Prognostic Insights: Determines the prognosis for a patient's long-term outcome.
- Multimodal AI Analysis: Combines digital pathology images and clinical data for comprehensive analysis.
- Fast Turnaround: Results are available within 2-3 days after specimen receipt.
- Tissue Preservation: Does not consume tissue samples; uses existing pathology slides.
Use Cases
- Identifying patients who will benefit from therapy intensification.
- Guiding treatment decisions for men with localized prostate cancer.
- Supporting shared decision-making between clinicians and patients.
- Personalizing treatment approaches based on individual patient characteristics.
- Expediting treatment planning with rapid results.
